NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference, scheduled for June 17-18, 2026. Dave Rosa, President and Chief Executive Officer, will attend the conference in Las Vegas, Nevada, where he is set to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time in TRACK 6 - Raphael 3.
During the presentation, Mr. Rosa will provide commercialization updates and anticipated milestones for the OneRF platform, which is designed for the treatment of the brain, pain management, and advanced drug delivery. The OneRF system, including the OneRF Ablation System for the brain and the OneRF Trigeminal Nerve Ablation System, has received FDA clearance and offers diagnostic and therapeutic functions that could reduce hospitalizations, lower costs, and improve patient outcomes. NeuroOne’s technology portfolio also includes Evo Cortical Electrodes and Evo sEEG Electrodes, all part of a minimally invasive, high-definition electrode platform.
In addition to the presentation, Mr. Rosa participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference, which can be viewed here. The webcast of the presentation will be accessible via a link on the Planet MicroCap website, available here. For more information on the conference or to schedule a meeting with management, interested parties may contact the conference representative or email the company at NMTC@mzgroup.us, or call Chris Tyson at (949) 491-8235.
NeuroOne continues to engage in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. The company’s focus remains on transforming surgical diagnosis and treatment of neurological disorders through innovative technology. The Planet MicroCap Las Vegas conference provides a platform for emerging growth companies like NeuroOne to connect with institutional investors and showcase their progress.
As of the announcement, NeuroOne’s stock trades on Nasdaq under the ticker NMTC. The company’s devices are subject to federal law, which restricts them to sale by or on the order of a physician. More information about NeuroOne and its products can be found on its website at nmtc1.com.
